Tim-3调节NF-κB/STAT3通路对肝癌血管生成及迁移的作用

被引:0
|
作者
彭修岩 [1 ]
朱远飞 [1 ]
林华鹏 [2 ]
机构
[1] 济宁医学院
[2] 济宁市第一人民医院肝胆外科
关键词
Tim-3; 肝细胞癌; NF-κB/STAT3; 血管生成;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
摘要
探究Tim-3在肝细胞癌进展中可能的作用机制,组织芯片分析Tim-3表达与肝细胞癌预后的相关性。将Tim-3过表达慢病毒及Tim-3 RNAi-Easy慢病毒转染人肝癌细胞SMMC-7721、BEL-7404、HuH-7,建立Tim-3的过表达(OE)和敲低(KD)细胞模型,分别用病毒CON335、CON313感染构建过表达对照组(OENC)及敲低对照组(KDNC)。Western blot检测鉴定Tim-3蛋白表达模型。实验分4组:OENC组、OE组、KDNC组、KD组。CCK-8细胞毒性实验、细胞克隆形成实验和细胞划痕损伤愈合实验检验4组肝癌细胞增殖和迁移能力。Western blot检测p-NF-κB、p-STAT3、IL-6、VEGFA、VEGFR1、VEGFR2蛋白表达。Tim-3在肝细胞癌组织中高表达且与不良预后相关(P<0.05)。敲低Tim-3抑制肝细胞癌的增殖、迁移,而过表达Tim-3促进肝细胞癌的增殖、迁移(P均<0.05);Western blot示,敲低Tim-3抑制p-NF-κB、p-STAT3、IL-6、VEGFA、VEGFR1、VEGFR2等指标的表达,过表达Tim-3则相反(P均<0.05)。Tim-3在肝细胞癌组织中高表达,且与肝细胞癌的不良预后相关,Tim-3可能成为肝癌诊断及预后评估的重要指标。Tim-3可以激活NF-κB/STAT3信号通路,并可能通过此通路促进肝细胞癌血管生成,从而促进肝细胞癌的增殖、迁移。
引用
收藏
页码:225 / 230
页数:6
相关论文
共 16 条
  • [1] Relationship between VEGF Family Members, Their Receptors and Cell Death in the Neoplastic Transformation of Colorectal Cancer
    Dakowicz, Dominika
    Zajkowska, Monika
    Mroczko, Barbara
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [2] IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma&#13;.[J].Xu Junnv;Lin Haifeng;Wu Gang;Zhu Mingyue;Li Mengsen.Frontiers in Oncology.2021,
  • [3] BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update..[J].Reig M;Forner A;Rimola J;FerrerFábrega J;Burrel M;GarciaCriado A;Kelley R K;Galle P R;Mazzaferro V;Salem R;Sangro B;Singal A G;Vogel A;Fuster J;Ayuso C;Bruix J.Journal of hepatology.2021, 3
  • [4] Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma
    Qin, Fanglu
    Lin, Shenghua
    Deng, Kun
    Qin, Junqi
    Xu, Zhanyu
    Yuan, Liqiang
    Wei, Jiangbo
    Sun, Yu
    Zheng, Tiaozhan
    Li, Shikang
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [5] NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein
    Song, Da
    Lan, Jingqin
    Chen, Yaqi
    Liu, Anyi
    Wu, Qi
    Zhao, Chongchong
    Feng, Yongdong
    Wang, Jing
    Luo, Xuelai
    Cao, Zhixin
    Cao, Xiaonian
    Hu, Junbo
    Wang, Guihua
    [J]. ONCOGENE, 2021, 40 (16) : 2952 - 2967
  • [6] VEGF in Signaling and Disease: Beyond Discovery and Development
    Apte, Rajendra S.
    Chen, Daniel S.
    Ferrara, Napoleone
    [J]. CELL, 2019, 176 (06) : 1248 - 1264
  • [7] Current topics in the surgical treatments for hepatocellular carcinoma
    Ban, Daisuke
    Ogura, Toshiro
    Akahoshi, Keiichi
    Tanabe, Minoru
    [J]. ANNALS OF GASTROENTEROLOGICAL SURGERY, 2018, 2 (02): : 137 - 146
  • [8] TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway..[J].Brian Tomkowicz;Eileen Walsh;Adam Cotty;Raluca Verona;Nina Sabins;Fred Kaplan;Sandy Santulli-Marotto;Chen-Ni Chin;Jill Mooney;Russell B Lingham;Michael Naso;Timothy McCabe.PLoS ONE.2017, 10
  • [9] Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis
    Tabrizian, Parissa
    Jibara, Ghalib
    Shrager, Brian
    Schwartz, Myron
    Roayaie, Sasan
    [J]. ANNALS OF SURGERY, 2015, 261 (05) : 947 - 955
  • [10] IL-6; through p-STAT3 rather than p-STAT1; activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study..[J].Kao Jung-Ta;Feng Chun-Lung;Yu Cheng-Ju;Tsai Shu-Mei;Hsu Ping-Ning;Chen Yao-Li;Wu Yi-Ying.BMC gastroenterology.2015, 1